Rankia USA Rankia Argentina Rankia Argentina Rankia Chile Rankia Chile Rankia Colombia Rankia Colombia Rankia España Rankia España Rankia México Rankia México Rankia Perú Rankia Perú Rankia Portugal Rankia Portugal
Acceder

Participaciones del usuario anaramos - Contenidos recomendados

11/08/20 09:50
Ha respondido al tema Farmas USA
OFF-TOPIC¿Por? Justo la semana antes de las vacaciones de Semana Santa de los niños. Me lo ha mandado la médica de cabecera...
Ir a respuesta
11/08/20 06:58
Ha respondido al tema Farmas USA
CPRXResultados ayer noche. Ligeramente mejores de lo esperado. Ahora mismo saca noticia de presentación de solicitud de patente. Cae ahora un 12% por fallo de Firdapse en miastenia gravis (estudio MuSK-MG). Si alguien puede aportar info, se agradecerá. Podría ser buena entrada. Edito: no se sabía. Habrá que ver dónde está la entrada buena. @lgonber ?“On a separate note, we are disappointed that the top-line results of our Phase 3 study for Firdapse® in anti-MuSK antibody positive myasthenia gravis patients did not replicate the robust positive results that were observed in the 2017 proof-of-concept study. We intend to continue to analyze the data and meet with our neuromuscular key opinion leaders to decide on our path forward for this program.”Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.08 by 12.5 percent. This is a 10 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $29.60 million which beat the analyst consensus estimate of $29.48 million by 0.41 percent. This is a 2.64 percent increase over sales of $28.84 million the same period last year.https://www.sec.gov/Archives/edgar/data/1369568/000119312520215047/d830820dex991.htm
Ir a respuesta
11/08/20 06:10
Ha respondido al tema Farmas USA
KPTIAyer salió una demanda de las típicas de un bufet dr abogados, por eso caía al inicio de sesión. No tiene mayor trascendencia.Putin afirma que tiene la vacuna para la covid-19. A mí el que ponga a su hija como ejemplo de cobaya me hace sospechar... Pero es obvio que la van a sacar los primeros.https://www.abc.es/internacional/abci-putin-afirma-rusia-tiene-vacuna-contra-covid-19-y-hija-probado-202008111045_noticia.htmlEdito: yo hoy me he hecho la serología a ver si tengo anticuerpos. Creo que lo pasé antes del cautiverio.
Ir a respuesta
10/08/20 08:10
Ha respondido al tema Farmas USA
KODKAcuerdo con el gobierno suspendido temporalmente por investigación de la FedThe U.S. International Development Finance Corp. has sidelined a loan agreement with Eastman Kodak (NYSE:KODK) to produce drugs that could be used to fight the coronavirus until allegations are cleared. The SEC is probing whether insider trading laws had been broken, citing "unusual trading activity" before the letter of intent was announced. The deal would provide the former photography company a $765M loan to help pay for factory changes needed to make pharmaceutical ingredients in short supply in the U.S.
Ir a respuesta
10/08/20 04:02
Ha respondido al tema Otras Aventuras de los Farmas USA
¿Por las circunstancias del momento o por algún criterio nuevo?Yo confío en que el año que viene me dé margen para volver a centrarme bien en la bolsa y recuperarlos .Entonces será año de largos, claro ;)<3
Ir a respuesta
07/08/20 09:36
Ha respondido al tema Farmas USA
HZNPColocación a 71$offering of 11.8M ordinary shares at $71.00/share, for expected net proceeds of ~$798.9M.Underwriters' over-allotment is an additional 1.77M shares.Net proceeds will be used to fund future acquisitions or licenses of medicine candidates and for general corporate purposes.Closing date is August 11.
Ir a respuesta
07/08/20 08:39
Ha respondido al tema Farmas USA
Efectivamente, como todo. Pero luego solo las farmacéuticas son las malas."safely, beautifully and inexpensively" dice.
Ir a respuesta
07/08/20 08:29
Ha respondido al tema Farmas USA
Orden ejecutiva de Trump para poner farmas en EE. UU. Enlaza con la ayuda a Kodak de la semana pasada."We will bring our pharmaceutical and medical supply chains home - we're going to bring them home where they belong - and we will end reliance on China," President Trump said after unveiling an action on domestic drug production. "We'll be making our product here - safely, beautifully and inexpensively. We're reasserting American economic independence." The executive order will help increase production of essential medicines, medical equipment and protective gear in the U.S., according to trade adviser Peter Navarro. "If we've learned anything from the China virus pandemic... we are dangerously overdependent on foreign nations.""If there's preferential treatment given to products manufactured in the U.S., then of course we will move more of our manufacturing to the U.S.," Teva Pharmaceutical CEO Kare Schultz said earlier this year. "If there’s no preferential treatment, then the basic economics will keep it the way it is right now."The plan comes as a proposal to lend $765M to Eastman Kodak (NYSE:KODK) draws scrutiny from the SEC. The loan, announced last week, would help the former photo giant produce drug ingredients from the U.S.https://seekingalpha.com/news/3602710-trump-signs-executive-action-to-boost-u-s-production-of-essential-drugs?mail_subject=wall-street-breakfast-jobs-report-overshadowed-by-tech-tensions&utm_campaign=nl-wall-street-breakfast&utm_content=link-22&utm_medium=email&utm_source=seeking_alpha
Ir a respuesta
07/08/20 06:48
Ha respondido al tema Farmas USA
Beño:Continua la expansión tecnológica, gracias al COVID, mientras la economía tradicional se hunde.https://inbestia.com/analisis/continua-la-expansion-tecnologica-gracias-al-covid-mientras-la-economia-tradicional-se-hunde
Ir a respuesta
05/08/20 09:26
Ha respondido al tema Farmas USA
KPTIRBC Capital mantiene con sobreponderar y PO 27 $La conferencia me ha parecido fantástica y muy profesional. Dejo aquí los catalizadores.- final additional monitoring data requested by EMA from the STORM study in patients with advanced refractory myeloma in September. - BOSTON data to the EMA in the fourth quarter of this year. The exact timing of potential regulatory decisions based on both the STORM and BOSTON data will be determined following feedback from EMA.- SIENDO study that should read out the end of next year in uterine cancer in the adjuvant settings and in patients with advanced uterine cancer. -additional trials ongoing in glioblastoma multiforme, both now in the front line in combination with radiation plus or minus temozolomide and in the second-line in combination with alkylator therapy. -additional studies that are also ongoing now, both investigator and company-sponsored in colorectal cancer and in lung cancer,-we hope to be sharing some additional data in other solid tumors toward the end of this yearFirst, we plan to submit additional STORM data and the full BOSTON data to EMA in the coming months. We hope to have greater clarity on the timing of future EMA regulatory decisions, following feedback from the agency. Next, we expect to share top line Phase 3 data from the SEAL study, evaluating selinexor in liposarcoma. Assuming positive results on the primary endpoint of PFS, we plan to file subsequent regulatory submissions. And finally, we anticipate initiating a confirmatory Phase 3 study of XPOVIO and DLBCL in support of our recent accelerated approval. And of course, we will work diligently through the remainder of the year to support our sNDA based on the BOSTON study as well as explore potential next steps for selinexor development in patients with severe COVID-19.As we look forward to the next several years, we will increasingly expand our activities in solid tumors, both as a single agent and in combination. These include uterine cancer with the ongoing Phase 3 SIENDO study, glioblastoma multiforme, both alone and in combination, colon cancer and lung cancer.Edito: dentro otro paquete a 15.56. Media 15.71
Ir a respuesta